Douglas Grossman Selected Research

Nevus (Nevi)

1/2022	A Randomized Double-blind Placebo-controlled Trial of Oral Aspirin for Protection of Melanocytic Nevi Against UV-induced DNA Damage.
11/2021	BRAFV600E induces reversible mitotic arrest in human melanocytes via microrna-mediated suppression of AURKB.
4/2020	Improved melanoma outcomes and survival in patients monitored by total body photography: A natural experiment.
1/2020	ASA Suppresses PGE2 in Plasma and Melanocytic Nevi of Human Subjects at Increased Risk for Melanoma.
1/2017	A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo.
7/2016	Reduction in nevus biopsies in patients monitored by total body photography.
7/2012	The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management.
12/2009	Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention.
6/2007	Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice.
1/2005	Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Douglas Grossman Research Topics

Disease

34	Melanoma (Melanoma, Malignant) 01/2022 - 01/2003
22	Neoplasms (Cancer) 01/2022 - 02/2003
10	Nevus (Nevi) 01/2022 - 01/2005
9	Pigmented Nevus (Melanocytic Nevus) 01/2022 - 01/2005
5	Neoplasm Metastasis (Metastasis) 09/2013 - 06/2007
4	Skin Neoplasms (Skin Cancer) 01/2021 - 02/2003
3	Carcinogenesis 01/2021 - 02/2003
2	COVID-19 01/2022 - 01/2021
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021 - 02/2003
2	Sunburn 01/2021 - 01/2021
2	Carcinoma (Carcinomatosis) 01/2019 - 02/2003
2	Cutaneous Malignant Melanoma 04/2013 - 03/2006
1	Basal Cell Carcinoma (Rodent Ulcer) 01/2022
1	Nevi and Melanomas 11/2021
1	Immune System Diseases (Immune Disorders) 06/2021
1	Tuberculosis (Tuberculoses) 06/2021
1	Inflammation (Inflammations) 01/2021
1	Brain Neoplasms (Brain Tumor) 01/2017
1	Retinoblastoma (Glioblastoma, Retinal) 01/2008
1	Hyperplasia 06/2004
1	Neurodermatitis (Lichen Simplex Chronicus) 06/2004

Drug/Important Bio-Agent (IBA)

13	SurvivinIBA 09/2013 - 01/2003
5	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2022 - 06/2014
4	Dinoprostone (PGE2)FDA Link 01/2022 - 10/2018
3	8-hydroxyguanineIBA 01/2022 - 01/2017
3	tributyl phosphate (TBP)IBA 04/2020 - 09/2006
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2017
3	Proteins (Proteins, Gene)FDA Link 08/2017 - 01/2004
3	Acetylcysteine (Siran)FDA LinkGeneric 01/2017 - 10/2007
3	AntioxidantsIBA 01/2017 - 10/2007
3	CaspasesIBA 10/2006 - 01/2004
2	Pyrimidine DimersIBA 01/2022 - 01/2021
2	Sunscreening Agents (Sunscreens)IBA 01/2021 - 01/2018
2	Adenosine Monophosphate (AMP)IBA 01/2020 - 01/2019
2	CytokinesIBA 01/2020 - 01/2004
2	Type 1 Melanocortin ReceptorIBA 01/2020 - 03/2006
2	Melanins (Melanin)IBA 10/2018 - 01/2013
2	Pharmaceutical PreparationsIBA 01/2017 - 12/2009
2	IntegrinsIBA 09/2013 - 10/2010
2	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2013 - 12/2009
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 10/2007 - 09/2007
2	Cisplatin (Platino)FDA LinkGeneric 09/2006 - 01/2003
1	MicroRNAs (MicroRNA)IBA 11/2021
1	Immune Checkpoint InhibitorsIBA 06/2021
1	AntibodiesIBA 06/2021
1	Immunologic Factors (Immunomodulators)IBA 06/2021
1	VaccinesIBA 06/2021
1	Vitamin D FDA LinkGeneric 06/2020
1	salicylurate (salicyluric acid)IBA 01/2020
1	SalicylatesIBA 01/2020
1	2,5-dihydroxybenzoic acid (gentisic acid)IBA 01/2020
1	Protein Kinases (Protein Kinase)IBA 01/2020
1	Anticarcinogenic AgentsIBA 01/2020
1	Adenylate KinaseIBA 10/2018
1	Celecoxib (Celebrex)FDA Link 10/2018
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 10/2018
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2017
1	tyrosine receptor (receptor, tyrosine)IBA 12/2017
1	Phosphotransferases (Kinase)IBA 12/2017
1	ThioredoxinsIBA 01/2017
1	IpilimumabIBA 09/2016
1	Interleukin-2 (IL2)IBA 09/2016
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 06/2014
1	PlasticsIBA 09/2013
1	Fibronectins (Fibronectin)IBA 09/2013
1	AgarIBA 09/2013
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 04/2013
1	Cyclin-Dependent Kinase Inhibitor p16IBA 04/2013
1	Selenomethionine (Sethotope)FDA Link 03/2013
1	SeleniumIBA 03/2013
1	methylselenic acidIBA 03/2013
1	Biological ProductsIBA 07/2012
1	Integrin alpha5IBA 10/2010
1	Integrin alpha5beta1IBA 10/2010
1	Cysteine (L-Cysteine)FDA Link 12/2009
1	Glutathione (Reduced Glutathione)IBA 12/2009
1	naamidine AIBA 07/2009
1	Antineoplastic Agents (Antineoplastics)IBA 07/2009
1	Caspase 3 (Caspase-3)IBA 07/2009
1	AlkaloidsIBA 07/2009
1	ParaffinIBA 11/2008
1	Formaldehyde (Formol)FDA Link 11/2008
1	Inhibitor of Apoptosis ProteinsIBA 01/2008
1	Sulfhydryl Compounds (Thiols)IBA 10/2007
1	beta-Galactosidase (Lactaid)IBA 10/2007
1	Drinking WaterIBA 10/2007
1	9,10-Dimethyl-1,2-benzanthraceneIBA 06/2007
1	High-Temperature Requirement A Serine Peptidase 2IBA 09/2006
1	Protease Inhibitors (Protease Inhibitor)IBA 09/2006
1	Cyclin-Dependent Kinase 4IBA 03/2006
1	Imatinib Mesylate (Gleevec)FDA Link 12/2004

Therapy/Procedure

6	Chemoprevention 01/2020 - 12/2009
5	Therapeutics 06/2021 - 05/2009
2	Oral Administration 01/2017 - 03/2013
1	Continuity of Patient Care 01/2022
1	Electrodes (Electrode) 01/2022
1	Immunotherapy 06/2021
1	Cell Transplantation 01/2017
1	Transplantation 01/2017
1	Intraperitoneal Injections 09/2013